Insider Selling: Hillstream Biopharma (NASDAQ:CNTN) Director Sells $43,375.00 in Stock

Hillstream Biopharma Inc. (NASDAQ:CNTN) Director Gary Stetz sold 12,500 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $3.47, for a total value of $43,375.00. Following the completion of the transaction, the director directly owned 134,175 shares of the company’s stock, valued at approximately $465,587.25. This trade represents a 8.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Hillstream Biopharma Stock Performance

CNTN stock opened at $3.10 on Friday. The firm has a market capitalization of $216.41 million, a P/E ratio of -2.70 and a beta of 1.44. The company has a 50-day moving average of $3.31. Hillstream Biopharma Inc. has a 52 week low of $1.08 and a 52 week high of $9.08.

Hillstream Biopharma (NASDAQ:CNTN) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.23) EPS for the quarter.

Analysts Set New Price Targets

Several research analysts have commented on CNTN shares. Wall Street Zen raised Hillstream Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings downgraded Hillstream Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 15th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

About Hillstream Biopharma

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.